Background Many infants admitted to hospital undergo repeated invasive procedures. Oral sucrose is frequently given to relieve procedural pain in neonates on the basis of its eff ect on behavioural and physiological pain scores. We assessed whether sucrose administration reduces pain-specifi c brain and spinal cord activity after an acute noxious procedure in newborn infants.
Introduction
International clinical guidelines recommend that oral sucrose is given to relieve procedural pain in neonates. 1 These recommendations are based on results from several randomised controlled clinical trials that conclude that sucrose is eff ective in reducing pain in preterm and term neonates. 2 Because many infants admitted to hospital undergo repeated invasive procedures, 3, 4 and because there is increasing evidence of short-term and long-term adverse neurodevelopmental consequences, [5] [6] [7] [8] [9] assessment of the eff ectiveness of sucrose analgesia in this patient group is essential. As a result, 44 randomised controlled trials investigating the eff ectiveness of sucrose analgesia in newborn infants are included in a recent Cochrane Review. 2 A major challenge in analgesic trials in the infant population is defi nition of a reliable, quantitative outcome measurement of pain because verbal reports and visual analogue scales cannot be used. 5, 10 The most commonly used outcome measures are based on behavioural and physiological observations, and many validated composite pain measurement instruments, such as the premature infant pain profi le (PIPP), are based on these observations. [11] [12] [13] These methods might not, however, be an appropriate outcome measure for neonatal analgesic trials [14] [15] [16] because they are largely based on human observation and judgment, 17 and, whereas pain experience and pain behaviour are linked in adults, 18 they might not be linked in neonates. For example, infants who do not display a change in facial expression after tissue damaging procedures might still display signifi cant cortical responses, 19 which suggests that infant behaviour is not a simple indication of pain activity in the brain. Many conditions, such as immaturity, neurological damage, and maternal drug misuse, can aff ect integrated sensorimotor function and consequent behaviour, [20] [21] [22] but might not necessarily aff ect sensory pain processing.
Single heel lances evoke specifi c nociceptive brain activity recorded with neonatal electroencephalography (EEG) 9, 23 and spinal nociceptive refl exes recorded with electromyography (EMG). 24 We undertook a randomised controlled trial of sucrose analgesia with use of this specifi c nociceptive brain activity as a direct measure of infant pain.
Methods

Study design and patients
We undertook a double-blind randomised study on the postnatal ward in the Elizabeth Garrett Anderson and Obstetric Wing, University College Hospital (UCH; London, UK), between Feb 25, 2009 , and March 25, 2010 . The participants were healthy newborn infants, born at 37-43 postmenstrual weeks, and less than 8 days old. Medical charts were reviewed and, at the time of study, infants were assessed as clinically stable. All infants were awake; not receiving analgesic drugs, sedatives, or other psychotrophic agents; had not been fed for at least 30 min before start of the study; were supine; and were selfventilating in air. Infants were not eligible for inclusion in the study if they showed signs of tissue damage on the lower limbs, had previous surgery, had intraventricular haemorrhage or periventricular leukomalacia, were born to diabetic mothers or opioid users, were asphyxiated at birth, or were born with congenital malformations or other genetic disorders. Infants were also excluded if they had contraindications to the administration of sucrose: high risk for necrotising enterocolitis, feeding intolerance, oesophageal atresia or tracheal oesophageal fi stula, or active phase persistent pulmonary hypertension.
Ethics approval was obtained from the UCH ethics committee and informed written parental consent was obtained before each procedure. The study conformed to the standards set by the Declaration of Helsinki and Good Clinical Practice guidelines.
Randomisation and masking
Treatment randomisation and dispensing was done off site at the UCH pharmacy. The pharmacy received the sterile sucrose solution (24% sucrose in purifi ed water) and sterile water samples from Inspiration Healthcare (Respironics, Murrysville, PA, USA) in individual 15 mL vials, which could not be visually distinguished by the packaging. 60 samples were randomised by a block design with a 1:1 allocation for sucrose and sterile water. The samples were separated into six blocks of ten, in which each block contained fi ve sucrose samples and fi ve sterile water samples. The pharmacy labelled each sample with a randomisation code that corresponded to the identity of the solutions. Randomisation was achieved with a computer-generated randomisation code. Only the hospital pharmacy had access to the randomisation codes that could be used to identify the solution. A sealed copy of the randomisation chart was also stored in the neonatal unit in case an adverse event was reported. Throughout the study the researchers, clinicians, participants, and parents were masked to the identity of the solutions. Inspiration Healthcare was not involved in the study design, data collection, or data analysis. No interim analysis was done in this study.
Procedures
The noxious stimulus was a heel lance done to collect a clinically necessary blood sample. The foot was not squeezed for at least 30 s after the heel lance to ensure that the recorded responses could be timed from one discrete event. This procedure was done without impairing the clinical blood collection. No heel lances were done solely for the purpose of the study. Before the administration of the sucrose or sterile water a nonnoxious control stimulus was applied to the infant's heel with a heel lancet. The lancet was rotated by 90° and placed against the heel, so that when the spring-loaded blade was released it did not contact the infants' heel. Infants experienced only the non-noxious tactile sensation and auditory click that occurs when the blade is released.
The sucrose solution or sterile water was administered directly onto the anterior surface of the tongue with a 1 mL syringe 2 min before a heel lance was done. In line with present clinical practice, the dose and expiry date of each solution was double-checked by two neonatal practitioners, and a neonatal nurse administered all solutions. A neonatal nurse was present during the studies and was responsible for the clinical care of the infants at all times. She was also responsible for reporting any adverse events to the consultant in charge.
Experimental recording techniques
A neonatal EEG cap (WaveGuard EEG cap, Advanced NeuroTechnology, Enschede, Netherlands) was used to record EEG activity in the infants. 32 recording electrodes were positioned according to the modifi ed international 10/20 electrode placement system at Fz, Fp1, Fp2, F3, F4, F7, F8, FT9, FT10, FC5, FC6, Cz, CPz, C3, C4, CP3, CP4, CP5, CP6, Pz, POz, P3, P4, P9, P10, PP07, PP08, T7, T8, Oz, O1, and O2. Reference and ground electrodes were placed at FCz and the chest, respectively. Electrode to skin impedance was kept to a minimum by massaging the head with an EEG prepping gel before the cap was placed on the head. Conductive EEG gel was placed in the electrode cups, with a syringe, before the EEG cap was placed on the head. The EEG cap was sterilised after each study by the UCH Sterile Services Department.
EEG activity, from 0·05 to 70 Hz, was recorded with the Neuroscan (Scan 4.3) SynAmps2 EEG/EP recording system (Compumedics US, Charlotte, NC, USA). Signals were digitised with a sampling rate of 2 kHz and had a resolution of 24 bit. A 50 Hz notch fi lter was used. The heel lance was time-locked to the EEG recording with an accelerometer attached to the upper surface of the lancet.
Respiration was monitored with a movement transducer placed on the abdomen and heart rate measured with lead 1 electrocardiograph (ECG) electrodes placed on the chest. Oxygen saturation and heart rate were continuously measured with a Nellcor N-560 transcutaneous pulse oximeter (Covidien-Nellcor and Puritan Bennett Boulderm, CO, USA) that was placed on the foot contralateral to the site of stimulation. Pulse oximetry data were downloaded from the oximeter to a recording computer as they were acquired.
EMG activity, from 1 to 500 Hz, was recorded from the ipsilateral biceps femoris muscle with self-adhesive bipolar surface silver/silver chloride (Ag/AgCl) electrodes. Electrode to skin impedance was reduced by rubbing the skin with an EEG prepping gel. Electrodes were secured with self-adherent wrap and electrode leads were tied together to minimise electrical interference.
Facial expression was recorded with a portable tripodmounted camcorder. A light emitting diode (LED), which fl ashed when either the non-noxious control event or noxious heel lance was done, was placed in the fi eld of view of the camcorder. Figure 1 shows the experimental time line.
Outcome measures
The primary outcome measure was pain-specifi c brain activity evoked by one time-locked heel lance, recorded with EEG and identifi ed by principal component analysis (PCA). Secondary measures were baseline behavioural and physiological measures, observational pain scores (PIPP), and spinal nociceptive refl ex withdrawal activity. The primary hypothesis was that administration of sucrose 2 min before a heel lance would reduce the evoked nociceptive-specifi c brain activity. 1500 ms EEG epochs corresponding to a noxious heel lance and non-noxious control event were considered for analysis (PCA). The EEG epochs included activity recorded 500 ms before and 1000 ms after each event. The segments were referenced to a common average, baseline corrected, high-pass fi ltered above 0·5 Hz, and aligned between 400 and 750 ms to correct for interindividual latency variability (maximum -20 to 50 ms). Infants were excluded from the analysis if technical failure occurred in the EEG recording or if movement artifact-defi ned as a voltage change greater than 50 μV over 50 ms in 15 or more electrodeswas identifi ed in the alignment window.
Nociceptive-specifi c activity was characterised at electrode site Cz because we have previously reported nociceptive-specifi c activity at this electrode site, 9, 23 and because studies in adults show that similar potentials recorded at Cz are sensitive to pharmacological analgesic drugs. 25 In the original research protocol we intended to use peak-to-peak amplitude detection. We deviated from the original protocol as instead we used PCA to analyse the data. This is an improved analytical technique that has been successfully used in EEG analysis and is more robust than peak-to-peak amplitude detection because it takes into account the overall signal rather than two single data points that can be easily aff ected by noise and are diffi cult to identify. We have successfully used this method in previous work to characterise evoked potentials generated after noxious and non-noxious stimulation in the human infant brain. 9, 23 PCA was used to decompose the EEG epochs recorded at Cz into basic waveforms, termed principal components. 26 Epochs were considered as variables and timepoints as observations; the resultant covariance matrix was selected as the association matrix. The principal components represent systematic variation in the amplitude of the signal across timepoints in a cluster of epochs. The extent to which each component is represented in an individual EEG epoch is quantifi ed by a unique weight. The weights of the fi rst two principal components, which accounted for 84% of the total variance, were considered for analysis.
The PIPP score was calculated for each infant on the basis of behavioural and physiological observations. 12 The facial expression component of the PIPP was analysed by trained observers (two neonatal research nurses) watching the videos for 30 s immediately after the heel lance. The videos were cut into 45 s epochs, which included 15 s before stimulus and 30 s after stimulus. The presence of each facial expression (nasolabial furrow, eye squeeze, and brow bulge) was assessed individually. The number of infants who had a facial expression score of zero was also calculated. 22 The observers were fully masked to the treatment allocation and stimulus type when they analysed the videos. The observers did not know whether they were viewing video footage after the heel lance or the control stimulation. An additional level of masking was imposed by mixing the videos with other non-trial video footage. The facial expression component of the PIPP was rescored by two observers in 15 of 60 (25%) of the videos to assess intrarater and inter-rater reliability, which was analysed by the Bland-Altman method. 27 Bland-Altman plots showed good reliability with little bias (intra-rater bias 0·07; inter-rater bias 0·73). The limits of agreement for the intra-rater re-test were ±1·62. The limits of agreement for the inter-rater comparison were ±1·49.
The mean heart rate and oxygen saturation in the 15 s before the heel lance, and the maximum heart rate and the minimum oxygen saturation in the 30 s after the heel lance were used to calculate the physiological indices in the PIPP score. Custom-made data analysis software, written in MATLAB, was used to automatically calculate the mean baseline heart rate and oxygen saturation. The software also calculated change in heart rate and oxygen saturation from the heel lance. The data used these parameters to automatically calculate the physiological indices in the PIPP score.
The behavioural state score was calculated by observing the infant's sleep state and facial movements on the video footage in the 15 s before the heel lance. The latency to facial expression change was defi ned as the latency when the fi rst PIPP facial feature (ie, nasolabial furrow, eye squeeze, and brow bulge) was observed after the heel lance in each infant.
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EMG analysis
2500 ms EMG epochs corresponding to a noxious heel lance were considered for analysis. The EMG epochs included activity recorded 1000 ms before and 1500 ms after each event. The segments were high-pass fi ltered above 10 Hz and rectifi ed. Latency to fl exion withdrawal refl ex activity was defi ned as the time after stimulus when the EMG activity exceeded three standard deviations of the pre-stimulus baseline. Magnitude of fl exion withdrawal refl ex activity was measured in 250 ms periods after stimulus by calculation of the root mean square activity. The summary parameter for the magnitude of the spinal nociceptive refl ex EMG activity was defi ned as the root mean square activity in 1000 ms after stimulus. Infants were not included in the EMG analysis when technical failure occurred in the EMG recording.
Statistical analysis
Data were analysed according to the trial protocol. A sample size of 40 infants had greater than 80% power to detect a 30% reduction in the amplitude of the nociceptivespecifi c brain activity as signifi cant (p<0·05; two-tailed).
We allowed for a total sample size of 60 infants (30 per group) to account for a high number of anticipated losses (ten per group) because of the possibility that technical failure could occur in any one of the physiological recordings (ie, video, EEG, or pulse oximetry; typically 20%; four per group) and that movement artifact could be recorded in the EEG (typically 20%; four per group). Two-way nested analysis of variance was applied to the principal component weights to assess the eff ect of stimulation type (non-noxious control, noxious heel lance) and treatment (sterile water, sucrose). With this analysis we assessed whether noxious stimulation generated a specifi c component and whether this component was aff ected by sucrose or sterile water administration. Nociceptive-specifi c brain activity was identifi ed by measurement of the principal components whose weights were signifi cantly greater after the noxious lance compared with non-noxious control.
As with our previous publications, only one nociceptivespecifi c principal component was identifi ed. To ensure that the activity defi ned in our participant sample could be generalised to other external samples, we compared the evoked activity with that reported in a previously published dataset 9 and calculated the correlation coeffi cient between the observations. Two-way nested analysis of variance was applied in the same way to the root mean square values of the EMG refl ex activity.
The eff ect of the treatment on all other outcome measures was summarised as mean values (with 95% CIs) and signifi cance of the diff erences tested with unpaired Student's t tests. A signifi cance level of 0·05 was used in all the tests. Data were analysed with MATLAB (version 7.8.0).
This study is registered, number ISRCTN78390996.
Role of the funding source
The sponsor of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication. Figure 2 shows the trial profi le. There were no deviations from the inclusion and exclusion criteria. 59 infants were included in our initial sample, of whom 44 were included in the fi nal analysis. Table 1 shows the characteristics of the fi nal population of infants. After sucrose or sterile water administration the mean heart rate, oxygen saturation, and behavioural scores in the 15 s before the heel lance did not diff er signifi cantly between infants who were given sucrose and those given sterile water (table 2) . After the heel lance, the PIPP score was signifi cantly lower in infants who were given sucrose than in those given sterile water; however, we recorded no signifi cant diff erence in the latency to change in facial expression between the two treatment groups (table 2). The number of infants who had a zero facial expression score after the noxious heel lance was signifi cantly higher in the sucrose group than in the sterile water group (table 2) .
Results
Nociceptive-specifi c brain activity was identifi ed by one principal component that was signifi cantly greater after the heel lance (mean principal component weight 0·09 [SE 0·02]) than after the non-noxious control event (0·03 [0·01]; p=0·006; fi gure 3A). The correlation coeffi cient between this component and a nociceptive-specifi c component calculated in an external sample of term infants in a previously published study 9 was 92% (p<0·0001). The nociceptive-specifi c brain activity did not diff er signifi cantly between infants who received sucrose (mean principal component weight 0·10 [SE 0·03]) and those who received sterile water (0·08 [0·02]; p=0·46; fi gure 3B).
Spinal refl ex withdrawal activity, recorded by EMG of the biceps femoris of the stimulated leg, was signifi cantly greater after the heel lance (mean activity 33·78 μV [SE 4·02] than after the non-noxious control event
Sucrose (N=20)
Sterile water (N=24) p value
Primary outcome
Nociceptive-specifi c brain activity (mean weight) 0·10 (0·04-0·16) 0·08 (0·04-0·12) 0·46
Secondary outcomes
Mean baseline heart rate (bpm) 132·6 (124·3-140·9) 131·8 (122·2-141·5) 0·90
Mean baseline oxygen saturation (%) 99·4% (98·8-100·1) 97·4% (95·0-99·8) 0·13
Baseline behavioural score (from PIPP)
Latency to change in facial expression (s) 3·8 (1·3-6·4) 3·5 (1·0-6·1) 0·86
Facial non-responders 7/20 (35%) 0/24 (0%) <0·0001
Mean nociceptive refl ex withdrawal activity (μV) 36·11 (24·20-48·02) 30·82 (18·51-43·13) 0·49
Mean latency to nociceptive refl ex withdrawal activity (ms) 363·3 (256·4-470·1) 413·5 (262·0-564·9) 0·56
Data are mean (95% CI) or n/N (%). bpm=beats per min. PIPP=premature infant pain profi le. 
Discussion
This randomised controlled trial measured the eff ect of oral sucrose on procedural pain in infants, with direct measures of brain and spinal cord activity as an outcome measure for pain. The results show that although, as previously reported, sucrose signifi cantly reduces the PIPP score-a composite observational behavioural and physiological measure 2 -it has no eff ect on the neural activity in sensory pain circuits in the brain or the spinal cord. Although true pain perception cannot be measured in non-verbal populations, neural activity in nociceptive pathways is a more direct measure than behavioural and physiological assessment. The fi nding that sucrose does not change neural activity strongly suggests that pain perception is not aff ected by this intervention.
Any measure of pain in this group is necessarily indirect, and whether the electrophysiological measures reported in this study are indicative of the conscious pain experience of the newborn infant cannot be shown. Nevertheless, behavioural and physiological output measures need integration and control of several somatic motor and autonomic circuits, which are aff ected by several developmental homoeostatic and external factors. 10, [19] [20] [21] By comparison, the nociceptive-evoked activity in the brain and spinal sensory circuits recorded in this study are a more direct measure of pain activity in the infant CNS. In the adult brain, the magnitude of nociceptive-evoked potentials directly correlates with perceived pain intensity. 28, 29 The nociceptive-evoked activity in fl exor muscles, which cause refl ex withdrawal of the limb, is also a proven functional measure of spinal and supraspinal pain processing. 30 Pharmacological analgesic drugs, such as tramadol and morphine, depress nociceptive-evoked brain activity and fl exion refl exes, and result in concurrent reduction in perceived pain intensity in adults. 25, 31, 32 Our results accord with previous trials showing that sucrose decreases infant PIPP scores, 2 but they show that such scores do not reliably refl ect nociceptive activity in the brain of newborn infants, possibly because of the site of action of sucrose in the brain. The reduction in nociceptive behaviour recorded after oral sucrose in young rats 33 persists after midbrain transection, suggesting that forebrain neural circuits are not needed for this eff ect. 34 Sucrose reduction of nociceptive withdrawal refl exes in adult rats-a conditioned eff ect of all hedonistic foods thought to prevent eating from ending-also involves brainstem endogenous inhibitory mechanisms. 35 Thus in infants exposed to noxious procedures, sucrose could mediate a brainstem inhibition of behaviour, and inhibit facial motor activity, while strong pain activation still occurs in the forebrain. This notion is especially important in view of the increasing evidence for short-term and long-term adverse eff ects of infant pain experience on neurodevelopment. [5] [6] [7] [8] [9] The absence of evidence for an analgesic action of sucrose in this study, together with uncertainty over the long-term benefi ts of repeated sucrose administration, 36 suggest that sucrose should not be used routinely for procedural pain in infants without further investigation.
This double-blind randomised controlled trial used new electrophysiological methods to assess the eff ectiveness of analgesic drugs in newborn infants. The conclusions that we can draw from this study are limited by the small sample size (n=44), which could mean that this study was not powered to observe subtle eff ects that sucrose might have on CNS processing. Signifi cant group diff erences in infant nociceptive brain activity have, however, been recorded in sample sizes of only 15 infants. 9 This single-centre trial should be repeated in a larger sample of infants, and this new method used to test the eff ect of other known pharmacological analgesic drugs, such as morphine.
In conclusion, our results show that although oral sucrose does reduce observed pain behaviour, it has no signifi cant eff ect on the magnitude of spinal nociceptive refl exes or on the acute activation of pain networks in the brain. Sucrose seems to blunt facial expression activity after painful procedures, but our data suggest that it does not reduce direct nociceptive activity in central sensory circuits, and therefore might not be an eff ective analgesic drug.
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